Analysts Set Assembly Biosciences, Inc. (NASDAQ:ASMB) Price Target at $42.75
by Doug Wharley · The Cerbat GemAssembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $42.75.
A number of equities research analysts recently commented on the stock. Guggenheim increased their target price on shares of Assembly Biosciences from $39.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, April 6th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research note on Thursday, March 26th. Wall Street Zen upgraded shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st.
Get Our Latest Stock Analysis on Assembly Biosciences
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of ASMB. Acadian Asset Management LLC increased its stake in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares in the last quarter. Geode Capital Management LLC increased its stake in Assembly Biosciences by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 3,312 shares in the last quarter. Ellsworth Advisors LLC acquired a new position in Assembly Biosciences during the 3rd quarter valued at approximately $852,000. Vanguard Group Inc. increased its stake in Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after purchasing an additional 248,287 shares in the last quarter. Finally, Patient Square Capital LP acquired a new position in Assembly Biosciences during the 3rd quarter valued at approximately $3,461,000. Institutional investors and hedge funds own 19.92% of the company’s stock.
Assembly Biosciences Stock Up 0.7%
NASDAQ:ASMB opened at $29.44 on Friday. Assembly Biosciences has a 52 week low of $9.68 and a 52 week high of $39.71. The firm has a 50 day moving average of $28.33 and a 200 day moving average of $30.30. The stock has a market capitalization of $466.92 million, a price-to-earnings ratio of -39.78 and a beta of 1.15.
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last posted its earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The company had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $7.42 million. As a group, analysts expect that Assembly Biosciences will post -6.87 EPS for the current year.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.
The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.